Sutro calls time on folate
At long last luvelta-T is shelved, and Sutro seeks a new focus.
Nuvation sets its sights on Voranigo
Safusidenib could eclipse the recently approved brain cancer drug, Nuvation claims.
Ono takes on Takeda in polycythemia vera
The Japanese group licenses sapablursen from Ionis for $280m.
No lost causes at Xilio and Lyell
The companies press on with vilastobart and IMPT-314... up to a point.
Arvinas’s degrader disappoints
The Pfizer-partnered vepdegestrant shows a benefit in ESR1 mutants, but not in all-comers.
